Affiliation:
1. Department of Laboratory Medicine1 and
2. the Second Department of Internal Medicine,2 Nagasaki University School of Medicine, Nagasaki 852-8501, Japan
Abstract
ABSTRACT
The in vitro activity of telithromycin (HMR3647), a new ketolide, against
Mycoplasma pneumoniae
was determined by the broth microdilution test using 41 clinical isolates obtained in Japan, as compared with those of five macrolides (erythromycin, clarithromycin, roxithromycin, azithromycin, and josamycin), minocycline, and levofloxacin. Telithromycin was less potent than azithromycin, but it was more active than four other macrolides, minocycline, and levofloxacin; its MICs at which 50 and 90% of the isolates tested were inhibited were both 0.00097 μg/ml, justifying clinical studies to determine its efficacy for treatment of
M. pneumoniae
.
Publisher
American Society for Microbiology
Subject
Infectious Diseases,Pharmacology (medical),Pharmacology
Cited by
37 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献